Medicare cuts hit MiMedx (NASDAQ: MDXG) as Q1 2026 sales fall

Rhea-AI Filing Summary

MiMedx Group reported Q1 2026 net sales of $59.0 million, down 33.1% from $88.2 million a year earlier, and recorded a net loss of $10.9 million versus prior-year net income of $7.0 million. Wound segment sales fell 59.7% to $22.6 million following January 1, 2026 Medicare reimbursement changes for skin substitutes, while Surgical sales grew 13.2% to $36.4 million.

Gross margin compressed to 70.6% from 81.2%, reflecting lower Wound pricing, an unfavorable mix and higher costs. The company ended the quarter with $159.8 million in cash and equivalents, $44.6 million in current liabilities, and $17.6 million of term debt outstanding, leaving its $75.0 million revolver undrawn.

Operating cash flow was $1.9 million, aided by strong receivables collections. MiMedx invested $5.0 million upfront for exclusive U.S. rights to RegenKit Wound Gel and noted a remaining $1.3 million profit-share obligation to TELA Bio. After quarter-end it announced a cost reduction initiative, including a workforce reduction of about 15% and expected one-time charges of roughly $4 million in Q2 2026.

Positive

• None.

Negative

• Wound segment shock and margin compression: Q1 2026 net sales fell 33.1% to $59.0M, driven by a 59.7% decline in Wound revenue after Medicare reimbursement changes, pushing MiMedx from $7.0M net income to a $10.9M net loss and reducing gross margin from 81.2% to 70.6%.

Insights

Healthcare equity analyst

Medicare-driven Wound weakness drove a sharp revenue decline and swing to loss.

MiMedx saw Q1 2026 net sales fall to $58.991M, a 33.1% drop year over year, with net results shifting from $7.023M income to a $10.860M loss. The core pressure came from Wound products, where sales declined 59.7% after Medicare reimbursement changes for skin substitutes.

Surgical revenue grew 13.2% to $36.374M, but that strength could not offset lower Wound pricing, volumes, and a mix shift, which reduced gross margin to 70.6% from 81.2%. Management responded by initiating an April 2026 cost reduction program, including a roughly 15% workforce reduction and about $4M of expected one-time charges in Q2 2026.

Despite weaker earnings, the balance sheet remains solid, with $159.773M of cash against $44.550M of current liabilities and $17.625M of term debt as of March 31, 2026. Access to a fully available $75.0M revolving credit facility and positive operating cash flow of $1.879M provide liquidity while the company adapts to the new reimbursement environment.

Key Figures

Net sales: $58.991M Net (loss) income: $(10.860M) Surgical net sales: $36.374M +5 more

8 metrics

Net sales $58.991M Three months ended March 31, 2026; down 33.1% YoY

Net (loss) income $(10.860M) Q1 2026 vs $7.023M net income in Q1 2025

Surgical net sales $36.374M Three months ended March 31, 2026; up 13.2% YoY

Wound net sales $22.617M Three months ended March 31, 2026; down 59.7% YoY

Gross margin 70.6% Q1 2026, decreased from 81.2% in Q1 2025

Cash and cash equivalents $159.773M Balance as of March 31, 2026

Long-term debt principal $17.625M Term Loan Facility principal outstanding as of March 31, 2026

Operating cash flow $1.879M Net cash provided by operating activities, Q1 2026

Key Terms

Medicare reimbursement changes, Revolving Credit Facility, cost reduction initiative, Profit Share Payments, +2 more

6 terms

Medicare reimbursement changes financial

"slower‑than‑expected recovery in the Wound Care market following the implementation of the January 1, 2026 Medicare reimbursement changes"

Revolving Credit Facility financial

"provided the Company with a $75.0 million Revolving Credit Facility and a $20.0 million Term Loan Facility"

A revolving credit facility is a type of loan that a business can borrow from whenever it needs money, up to a set limit. It’s like having a credit card for companies—allowing them to borrow, pay back, and borrow again as needed, providing flexibility for managing cash flow or funding short-term expenses.

cost reduction initiative financial

"In April 2026, the Company announced a cost reduction initiative intended to streamline operations and reduce operating expenses"

Profit Share Payments financial

"required to make payments (the “Profit Share Payments”) of between a minimum of $3.0 million and a maximum of $7.0 million"

Convertible Note Purchase Agreement financial

"entered into a Convertible Note Purchase Agreement (the “Vaporox Note”) with Vaporox, Inc."

A convertible note purchase agreement is a contract where an investor lends money to a company through a short-term loan that can later convert into shares instead of being repaid in cash. Think of it as giving a company a loan with an agreed option to swap that loan for ownership at a future financing; it matters to investors because the conversion terms determine potential ownership, risk, timing, and how much existing shareholders may be diluted.

fair value option financial

"The Company elected to account for the Vaporox Note pursuant to the Fair Value Option guidance prescribed by Accounting Standards Codification"

An accounting election that lets a company measure eligible financial assets and liabilities at their current market price, recording gains and losses in the income statement as those prices move. For investors it matters because choosing the fair value option makes reported profits and asset values respond immediately to market swings—like revaluing a house to today’s sale price—so it can increase earnings volatility while giving a more up‑to‑date view of value.

10-Q Quarterly Reports: What Changes Quarter to Quarter →

000137633912/312026Q1false1xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:puremdxg:service_sitemdxg:segment00013763392026-01-012026-03-3100013763392026-04-2300013763392026-03-3100013763392025-12-3100013763392025-01-012025-03-310001376339us-gaap:CommonStockMember2025-12-310001376339us-gaap:AdditionalPaidInCapitalMember2025-12-310001376339us-gaap:RetainedEarningsMember2025-12-310001376339us-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-310001376339us-gaap:CommonStockMember2026-01-012026-03-310001376339us-gaap:RetainedEarningsMember2026-01-012026-03-310001376339us-gaap:CommonStockMember2026-03-310001376339us-gaap:AdditionalPaidInCapitalMember2026-03-310001376339us-gaap:RetainedEarningsMember2026-03-310001376339us-gaap:CommonStockMember2024-12-310001376339us-gaap:AdditionalPaidInCapitalMember2024-12-310001376339us-gaap:RetainedEarningsMember2024-12-3100013763392024-12-310001376339us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-310001376339us-gaap:CommonStockMember2025-01-012025-03-310001376339us-gaap:RetainedEarningsMember2025-01-012025-03-310001376339us-gaap:CommonStockMember2025-03-310001376339us-gaap:AdditionalPaidInCapitalMember2025-03-310001376339us-gaap:RetainedEarningsMember2025-03-3100013763392025-03-310001376339us-gaap:EquipmentMember2026-03-310001376339us-gaap:EquipmentMember2025-12-310001376339us-gaap:FurnitureAndFixturesMember2026-03-310001376339us-gaap:FurnitureAndFixturesMember2025-12-310001376339us-gaap:LeaseholdImprovementsMember2026-03-310001376339us-gaap:LeaseholdImprovementsMember2025-12-310001376339us-gaap:ConstructionInProgressMember2026-03-310001376339us-gaap:ConstructionInProgressMember2025-12-310001376339mdxg:AssetRetirementCostMember2026-03-310001376339mdxg:AssetRetirementCostMember2025-12-310001376339us-gaap:PatentsMember2026-03-310001376339us-gaap:PatentsMember2025-12-310001376339us-gaap:LicensingAgreementsMember2026-03-310001376339us-gaap:LicensingAgreementsMember2025-12-310001376339mdxg:SupplierRelationshipsMember2026-03-310001376339mdxg:SupplierRelationshipsMember2025-12-310001376339us-gaap:TrademarksAndTradeNamesMember2026-03-310001376339us-gaap:TrademarksAndTradeNamesMember2025-12-310001376339us-gaap:TrademarksAndTradeNamesMember2026-03-310001376339us-gaap:TrademarksAndTradeNamesMember2025-12-310001376339mdxg:PatentsInProcessMember2026-03-310001376339mdxg:PatentsInProcessMember2025-12-310001376339us-gaap:RevolvingCreditFacilityMembermdxg:CitizensCreditAgreementMemberus-gaap:LineOfCreditMember2024-01-190001376339us-gaap:SecuredDebtMembermdxg:CitizensCreditAgreementMemberus-gaap:LineOfCreditMember2024-01-190001376339us-gaap:RevolvingCreditFacilityMembermdxg:CitizensCreditAgreementMemberus-gaap:LineOfCreditMember2026-03-310001376339us-gaap:BaseRateMembermdxg:CitizensCreditAgreementMembersrt:MinimumMemberus-gaap:LineOfCreditMember2024-01-192024-01-190001376339us-gaap:BaseRateMembermdxg:CitizensCreditAgreementMembersrt:MaximumMemberus-gaap:LineOfCreditMember2024-01-192024-01-190001376339us-gaap:SecuredOvernightFinancingRateSofrMembermdxg:CitizensCreditAgreementMembersrt:MinimumMemberus-gaap:LineOfCreditMember2024-01-192024-01-190001376339us-gaap:SecuredOvernightFinancingRateSofrMembermdxg:CitizensCreditAgreementMembersrt:MaximumMemberus-gaap:LineOfCreditMember2024-01-192024-01-190001376339us-gaap:BridgeLoanMemberus-gaap:SecuredOvernightFinancingRateSofrMembermdxg:CitizensCreditAgreementMemberus-gaap:LineOfCreditMember2024-01-192024-01-190001376339us-gaap:SecuredDebtMemberus-gaap:SecuredOvernightFinancingRateSofrMembermdxg:CitizensCreditAgreementMemberus-gaap:LineOfCreditMember2026-03-310001376339us-gaap:SecuredDebtMembermdxg:CitizensCreditAgreementMemberus-gaap:LineOfCreditMember2026-03-310001376339us-gaap:SecuredDebtMembermdxg:CitizensCreditAgreementMemberus-gaap:LineOfCreditMember2025-12-310001376339us-gaap:SecuredDebtMembermdxg:CitizensCreditAgreementMemberus-gaap:LineOfCreditMember2026-01-012026-03-310001376339us-gaap:SecuredDebtMembermdxg:CitizensCreditAgreementMemberus-gaap:LineOfCreditMember2025-01-012025-03-310001376339us-gaap:RevolvingCreditFacilityMembermdxg:CitizensCreditAgreementMemberus-gaap:LineOfCreditMember2025-01-012025-03-310001376339us-gaap:RevolvingCreditFacilityMembermdxg:CitizensCreditAgreementMemberus-gaap:LineOfCreditMember2026-01-012026-03-310001376339us-gaap:RestrictedStockUnitsRSUMember2026-01-012026-03-310001376339us-gaap:RestrictedStockUnitsRSUMember2025-01-012025-03-310001376339us-gaap:EmployeeStockOptionMember2026-01-012026-03-310001376339us-gaap:EmployeeStockOptionMember2025-01-012025-03-310001376339us-gaap:PerformanceSharesMember2026-01-012026-03-310001376339us-gaap:PerformanceSharesMember2025-01-012025-03-310001376339us-gaap:EmployeeStockMember2026-01-012026-03-310001376339us-gaap:EmployeeStockMember2025-01-012025-03-310001376339us-gaap:RestrictedStockUnitsRSUMember2026-01-012026-03-310001376339us-gaap:RestrictedStockUnitsRSUMember2025-01-012025-03-310001376339us-gaap:EmployeeStockOptionMember2026-01-012026-03-310001376339us-gaap:EmployeeStockOptionMember2025-01-012025-03-310001376339us-gaap:PerformanceSharesMember2026-01-012026-03-310001376339us-gaap:PerformanceSharesMember2025-01-012025-03-310001376339srt:MinimumMembermdxg:TELAAPAMember2024-03-152024-03-150001376339srt:MaximumMembermdxg:TELAAPAMember2024-03-152024-03-150001376339mdxg:TELAAPAMember2024-03-152024-03-150001376339mdxg:TELAAPAMemberus-gaap:ResearchAndDevelopmentArrangementMember2026-03-310001376339mdxg:TELAAPAMember2026-01-012026-03-310001376339mdxg:SurgicalMember2026-01-012026-03-310001376339mdxg:SurgicalMember2025-01-012025-03-310001376339mdxg:WoundMember2026-01-012026-03-310001376339mdxg:WoundMember2025-01-012025-03-310001376339mdxg:VaporoxAgreementMember2025-04-012025-06-300001376339mdxg:VaporoxAgreementMember2026-03-310001376339mdxg:RegenLabUSALLCMember2026-01-012026-01-310001376339srt:ScenarioForecastMembermdxg:A2026WorkforceReductionMemberus-gaap:SubsequentEventMember2026-04-012026-04-300001376339srt:ScenarioForecastMemberus-gaap:SubsequentEventMember2026-04-012026-06-300001376339us-gaap:SubsequentEventMember2026-04-300001376339us-gaap:SubsequentEventMember2026-04-012026-04-30

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the

Quarterly Period Ended

March 31, 2026

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____________________to______________________

Commission File Number 001-35887

MIMEDX GROUP, INC.

(Exact name of registrant as specified in its charter)

Florida						26-2792552
(State or other jurisdiction of incorporation or organization)						(I.R.S. Employer Identification No.)

1775 West Oak Commons Ct NE Marietta, GA						30062
(Address of principal executive offices)						(Zip Code)

(770) 651-9100

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Stock, par value $0.001 per share			MDXG			The Nasdaq Stock Market

Securities registered pursuant to Section 12(g) of the Act: None.

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer x

Accelerated filer ¨

Non-accelerated filer ¨

Smaller reporting company ☐

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐ No x

There were 148,945,731 shares of the registrant’s common stock, par value $0.001 per share, outstanding as of April 23, 2026.

Table of Contents

Part I     FINANCIAL INFORMATION
Item 1			Financial Statements (Unaudited)
			Condensed Consolidated Balance Sheets			5
			Condensed Consolidated Statements of Operations			6
			Condensed Consolidated Statements of Stockholders’ Equity			7
			Condensed Consolidated Statements of Cash Flows			8
			Notes to the Condensed Consolidated Financial Statements			9
Item 2			Management’s Discussion and Analysis of Financial Condition and Results of Operations			17
Item 3			Quantitative and Qualitative Disclosures About Market Risk			20
Item 4			Controls and Procedures			20
Part II   OTHER INFORMATION
Item 1			Legal Proceedings			22
Item 1A			Risk Factors			22
Item 2			Unregistered Sales of Equity Securities and Use of Proceeds			22
Item 3			Defaults upon Senior Securities			22
Item 4			Mine Safety Disclosures			22
Item 5			Other Information			22
Item 6			Exhibits			22
Signatures						22

3

Explanatory Note and Important Cautionary Statement Regarding Forward-Looking Statements

As used herein, the terms “MIMEDX,” the “Company,” “we,” “our” and “us” refer to MiMedx Group, Inc., a Florida corporation, and its consolidated subsidiaries as a combined entity, except where it is clear that the terms mean only MiMedx Group, Inc.

Certain statements made in this Quarterly Report on Form 10-Q (this “Quarterly Report”) are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and section 21E of the Securities Exchange Act of 1934, as amended. All statements herein relating to events or results that may occur in the future are forward-looking statements, including, without limitation, statements regarding the following:

•our strategic focus and current business priorities, including broadening of our product portfolio, and our ability to implement these priorities;

•our expectations regarding demand for our Wound products in response to recent changes in Medicare reimbursement for skin substitutes;

•our expectations of the impact of our cost reduction initiatives;

•our expectations regarding costs relating to compliance with regulatory requirements;

•our expectations regarding capital allocation;

•our expectations regarding future growth;

•our expectations regarding the outcome of pending litigation and investigations;

•our expectations regarding future income tax liability;

•demographic and market trends; and

•our ability to compete effectively.

Forward-looking statements generally can be identified by words such as “expect,” “will,” “change,” “intend,” “seek,” “target,” “future,” “plan,” “continue,” “potential,” “possible,” “could,” “estimate,” “may,” “anticipate,” “to be” and similar expressions. These statements are based on numerous assumptions and involve known and unknown risks, uncertainties and other factors that could significantly affect the Company’s operations and may cause the Company’s actual actions, results, financial condition, performance or achievements to differ materially from any future actions, results, financial condition, performance or achievements expressed or implied by any such forward-looking statements. Factors that may cause such a difference include, without limitation, those discussed under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025 (our “2025 Form 10-K”), filed with the Securities and Exchange Commission (“SEC”) on February 25, 2026 and those discussed in Part II, Item 1A, Risk Factors, if any.

Unless required by law, the Company does not intend, and undertakes no obligation, to update or publicly release any revision to any forward-looking statements, whether as a result of the receipt of new information, the occurrence of subsequent events, a change in circumstances or otherwise. Each forward-looking statement contained in this Quarterly Report is specifically qualified in its entirety by the aforementioned factors. Readers are advised to carefully read this Quarterly Report in conjunction with the important disclaimers set forth above prior to reaching any conclusions or making any investment decisions and not to place undue reliance on forward-looking statements, which speak only as of the date of the filing of this Quarterly Report with the SEC.

4

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

MIMEDX GROUP, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except share data)

(unaudited)

			March 31, 2026						December 31, 2025
ASSETS
Current assets:
Cash and cash equivalents			$	159,773					$	166,121
Accounts receivable, net			46,034						75,707
Inventory			26,228						25,340
Other current assets			8,291						10,303
Total current assets			240,326						277,471
Property and equipment, net			4,756						4,713
Deferred tax asset, net			24,127						19,596
Goodwill			19,441						19,441
Intangible assets, net			13,140						14,158
Other assets			6,886						7,274
Total assets			$	308,676					$	342,653
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Current portion of long term debt			$	1,500					$	1,500
Accounts payable			11,464						14,528
Accrued compensation			14,524						31,065
Accrued expenses			11,008						11,383
Other current liabilities			6,054						5,790
Total current liabilities			44,550						64,266
Long term debt, net			16,094						16,467
Other liabilities			5,096						5,372
Total liabilities			$	65,740					$	86,105
Stockholders' equity
Common stock; $0.001 par value; 250,000,000 shares authorized; 148,931,360 issued and outstanding at March 31, 2026 and 148,093,920 issued and outstanding at December 31, 2025			149						148
Additional paid-in capital			296,328						299,081
Accumulated deficit			(53,541)						(42,681)
Total stockholders' equity			242,936						256,548
Total liabilities and stockholders’ equity			$	308,676					$	342,653

See notes to unaudited condensed consolidated financial statements

5

MIMEDX GROUP, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except share and per share data)

(unaudited)

			Three Months Ended March 31,
			2026						2025
Net sales			$	58,991					$	88,205
Cost of sales			17,368						16,558
Gross profit			41,623						71,647
Operating expenses:
Selling, general and administrative			53,231						59,969
Research and development			4,140						3,328
Amortization of intangible assets			301						99
Operating income			(16,049)						8,251
Other expense, net
Interest income, net			886						506
Other expense, net			(168)						(145)
(Loss) income before income tax			(15,331)						8,612
Income tax provision			4,471						(1,589)
Net (loss) income			$	(10,860)					$	7,023
Basic net (loss) income per common share			$	(0.07)					$	0.05
Diluted net (loss) income per common share			$	(0.07)					$	0.05
Weighted average common shares outstanding - basic			148,446,017						147,272,324
Weighted average common shares outstanding - diluted			148,446,017						149,677,452

See notes to unaudited condensed consolidated financial statements

6

MIMEDX GROUP, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(in thousands, except share data)
(unaudited)

			Common Stock Issued												Additional Paid-In												Accumulated
			Shares						Amount						Capital																		Deficit						Total
Balance at December 31, 2025			148,093,920						$	148					$	299,081																	$	(42,681)					$	256,548
Share-based compensation expense reversal			—						—						(1,687)																		—						(1,687)
Employee stock purchase plan			192,278						—						835																		—						835
Issuance of restricted stock, net			645,162						1						(1,901)																		—						(1,900)
Net loss			—						—						—																		(10,860)						(10,860)
Balance at March 31, 2026			148,931,360						$	149					$	296,328																	$	(53,541)					$	242,936

			Common Stock Issued												Additional Paid-In												Accumulated
			Shares						Amount						Capital																		Deficit						Total
Balance at December 31, 2024			146,932,032						$	147					$	284,219																	$	(91,259)					$	193,107
Share-based compensation expense			—						—						4,259																		—						4,259
Employee stock purchase plan			149,457						—						848																		—						848
Issuance of restricted stock, net			526,133						1						(2,462)																		—						(2,461)
Net income			—						—						—																		7,023						7,023
Balance at March 31, 2025			147,607,622						$	148					$	286,864																	$	(84,236)					$	202,776

7

MIMEDX GROUP, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands)

(unaudited)

			Three Months Ended March 31,
			2026						2025
Cash flows from operating activities:
Net (loss) income from operations			$	(10,860)					$	7,023
Adjustments to reconcile net (loss) income to net cash flows provided by operating activities
Depreciation and amortization			1,617						3,203
Credit loss expense			1,464						742
Non-cash lease expenses			330						307
Share-based compensation			(1,696)						4,262
Deferred income taxes			(4,531)						621
Other			118						166
Increase (decrease) in cash resulting from changes in:
Accounts receivable			28,209						(7,203)
Inventory			(889)						(263)
Other assets			2,012						(1,032)
Accounts payable			1,936						1,460
Accrued compensation			(15,706)						(4,073)
Accrued expenses			(375)						(73)
Other liabilities			250						159
Net cash flows provided by operating activities			1,879						5,299
Cash flows from investing activities:
Cash paid for acquisitions			(5,000)						—
Purchases of equipment			(570)						(377)
Patent application costs			(72)						(29)
Net cash flows used in investing activities			(5,642)						(406)
Cash flows from financing activities:
Stock repurchased for tax withholdings on vesting of restricted stock			(1,901)						(2,458)
Principal payments on Citizens Term Loan Facility			(375)						(250)
Cash paid for Profit Share Payment (Note 12)			(309)						(170)
Net cash flows used in financing activities			(2,585)						(2,878)
Net change in cash			(6,348)						2,015
Cash and cash equivalents, beginning of period			166,121						104,416
Cash and cash equivalents, end of period			$	159,773					$	106,431

See notes to unaudited condensed consolidated financial statements

8

MIMEDX GROUP, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED MARCH 31, 2026 AND 2025

1.Nature of Business

MiMedx Group, Inc. (together with its subsidiaries, except where the context otherwise requires, “MIMEDX,” or the “Company”) is a pioneer and leader focused on helping humans heal. With more than a decade of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX is dedicated to providing a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company’s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. All of the Company’s products sold in the United States are regulated by the United States Food and Drug Administration (“FDA”).

The Company’s product portfolio and product development focuses on Surgical and Wound markets.

The Company’s business is focused primarily on the United States, but the Company also has an emerging commercial presence in several international locations, including Japan.

2.Significant Accounting Policies

Please see Note 2, Significant Accounting Policies, to the Company’s Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 (the “2025 Form 10-K”), filed with the Securities and Exchange Commission (“SEC”) on February 25, 2026 for a description of all significant accounting policies.

Basis of Presentation

The unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation of the results of operations for the periods presented have been included. The operating results for the three months ended March 31, 2026 and 2025 are not necessarily indicative of the results that may be expected for the full fiscal year. The balance sheet as of December 31, 2025 was derived from the audited consolidated financial statements at that date, but does not include all of the information and footnotes required by GAAP for complete financial statements.

These unaudited condensed consolidated financial statements should be read in conjunction with the historical consolidated financial statements of the Company included in the 2025 Form 10-K.

Principles of Consolidation

The condensed consolidated financial statements include the accounts of MiMedx Group, Inc. and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated upon consolidation.

Use of Estimates

GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported condensed consolidated statements of operations during the reporting period. Actual results could differ from those estimates. Significant estimates include estimated useful lives and potential impairment of property and equipment, estimates of impairment for goodwill and intangible assets, estimates of useful lives for intangible assets, estimates of loss for contingent liabilities, estimate of allowance for doubtful accounts, estimates of fair value of and the probable achievement of performance conditions associated with share-based payment awards, estimates of returns and allowances, estimate of fair value of the remaining Profit Share Payments (as defined below), determination of fair value of hybrid instruments valued under the Fair Value Option, and valuation of deferred tax assets.

Recently Issued Accounting Standards Not Yet Adopted

Accounting Standards Update 2024-04 - Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures

9

In November 2024, the FASB issued ASU 2024-03, “Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40),” which requires disaggregated disclosure of certain income statement expenses within the footnotes to the financial statements. ASU 2024-03 is intended to address requests from investors for more detailed information about the types of expenses in commonly presented expense captions such as cost of sales, selling, general and administrative expenses, and research and development. Adoption is required for annual periods beginning after December 15, 2026 and interim periods within annual periods beginning after December 15, 2027. The Company is currently evaluating the impact of this standard on its consolidated financial statements.

All other ASUs issued and not yet effective as of March 31, 2026, and through the date of this report, were assessed and determined to be either not applicable or are expected to have minimal impact on the Company’s current and future financial position and results of operations.

3. Accounts Receivable, Net

Accounts receivable, net, consisted of the following (in thousands):

			March 31, 2026						December 31, 2025
Accounts receivable, gross			$	55,572					$	84,410
Less: allowance for credit losses			(9,538)						(8,703)
Accounts receivable, net			$	46,034					$	75,707

Activity related to the Company’s allowance for credit losses for the three months ended March 31, 2026 and 2025 were as follows (in thousands):

Balance at December 31, 2025			$	8,703
Credit loss expense			1,464
Write-offs			(629)
Balance at March 31, 2026			$	9,538

Balance at December 31, 2024			$	3,132
Credit loss expense			742
Write-offs			—
Balance at March 31, 2025			$	3,874

4.     Inventory

Inventory consisted of the following (in thousands):

			March 31, 2026						December 31, 2025
Raw materials			$	1,064					$	1,221
Work in process			4,224						8,666
Finished goods			20,940						15,453
Inventory			$	26,228					$	25,340

10

5.    Property and Equipment, Net

Property and equipment, net, consisted of the following (in thousands):

			March 31, 2026						December 31, 2025
Laboratory and clean room equipment			$	15,685					$	15,739
Furniture and equipment			1,966						2,008
Leasehold improvements			8,957						8,977
Construction in progress			1,124						612
Asset retirement cost			884						875
Property and equipment, gross			28,616						28,211
Less: accumulated depreciation and amortization			(23,860)						(23,498)
Property and equipment, net			$	4,756					$	4,713

Depreciation expense was the following (in thousands):

			Three Months Ended March 31,
			2026						2025
Depreciation Expense			$	528					$	558

6.     Intangible Assets, Net

Intangible assets, net, are summarized as follows (in thousands):

			March 31, 2026												December 31, 2025
			Gross Carrying Amount			Accumulated Amortization			Net Carrying Amount						Gross Carrying Amount			Accumulated Amortization			Net Carrying Amount
Amortized intangible assets
Patents and know-how			$	10,666		$	(8,898)		$	1,768					$	10,666		$	(8,843)		$	1,823
Licenses			1,500			(424)			1,076						1,500			(188)			1,312
Supplier relationships			12,660			(3,477)			9,183						12,660			(2,678)			9,982
Tradenames and trademarks			—			—			—						12,497			(12,497)			—
Total amortized intangible assets			$	24,826		$	(12,799)		$	12,027					$	37,323		$	(24,206)		$	13,117
Unamortized intangible assets:
Tradenames and trademarks			$	1,008					$	1,008					$	1,008					$	1,008
Patents in Process			105						105						33						33
Total intangible assets			$	25,939					$	13,140					$	38,364					$	14,158

11

7. Accrued Expenses

Accrued expenses consisted of the following (in thousands):

			March 31, 2026						December 31, 2025
Commissions to sales agents			$	4,450					$	5,390
Accrued rebates			1,549						1,130
Estimated sales returns			942						2,435
Legal costs			2,717						978
Other			1,350						1,450
Accrued expenses			$	11,008					$	11,383

8.    Long Term Debt, Net

Citizens Credit Agreement

On January 19, 2024, the Company entered into the Citizens Credit Agreement, which provided the Company with a $75.0 million Revolving Credit Facility and a $20.0 million Term Loan Facility. The Company had no outstanding borrowings under the Revolving Credit Facility as of March 31, 2026. The Term Loan Facility matures on January 19, 2029 (the “Maturity Date”).

Borrowings under the Citizens Credit Agreement bear interest at a rate per annum equal to (i) the Alternate Base Rate, as defined therein, or (ii) a Term SOFR as defined therein, in each case plus an applicable margin ranging from 1.25% and 2.50% with respect to Alternate Base Rate borrowings and 2.25% and 3.50% for Term SOFR borrowings, plus a fallback provision of 0.1%. The Term Loan Facility carried an interest rate of 6.0% as of March 31, 2026.

The noncurrent portion of the Term Loan Facility was $16.1 million and $16.5 million as of March 31, 2026 and December 31, 2025, respectively. The current portion of the Term Loan Facility was $1.5 million as of both March 31, 2026 and December 31, 2025.

Interest expense related to the Term Loan Facility included in interest income, net in the unaudited condensed consolidated statements of operations was $0.3 million and $0.4 million for the three months ended March 31, 2026 and March 31, 2025, respectively.

Interest expense related to the Revolving Credit Facility included in interest income, net in the unaudited condensed consolidated statements of operations was $0.1 million for the three months ended March 31, 2026 and March 31, 2025.

A summary of principal payments due on the Term Loan Facility, by year, from March 31, 2026 through maturity are as follows (in thousands):

Year ending December 31,			Principal
2026 (excluding the three months ended March 31, 2026)			$	1,125
2027			1,500
2028			2,000
2029			13,000
Outstanding principal			$	17,625

                                                                                

As of March 31, 2026, the fair value of the Term Loan Facility was $16.9 million. This valuation was calculated based on a series of Level 2 and Level 3 inputs, including a discount rate based on the credit risk spread of debt instruments of similar risk character in reference to U.S. Treasury instruments with similar maturities, with an incremental risk premium for risk factors specific to the Company. Fair value was calculated by discounting the remaining cash flows associated with the Term Loan Facility to March 31, 2026 using this discount rate.

9. Net Income Per Common Share

Net income per common share is calculated using two methods: basic and diluted.

12

Basic Net Income Per Common Share

The following table provides a reconciliation of net income from continuing operations and calculation of basic net income per common share for each of the three months ended March 31, 2026 and 2025 (in thousands, except share and per share amounts).

			Three Months Ended March 31,
			2026						2025
Net (loss) income			$	(10,860)					$	7,023
Weighted average common shares outstanding			148,446,017						147,272,324
Basic net (loss) income per common share			$	(0.07)					$	0.05

Diluted Net Income Per Common Share

The following table sets forth the computation of diluted net income per common share (in thousands, except share and per share amounts):

			Three Months Ended March 31,
			2026						2025
Net (loss) income			$	(10,860)					$	7,023
Weighted average shares outstanding			148,446,017						147,272,324
Adjustments:
Potential common shares
Restricted stock unit awards			—						1,565,979
Outstanding stock options			—						598,798
Performance stock unit awards			—						230,549
Employee stock purchase plan			—						9,802
Total adjustments			—						2,405,128
Weighted average shares outstanding adjusted for potential common shares			148,446,017						149,677,452
Diluted net (loss) income per common share			$	(0.07)					$	0.05

(a) Weighted average common shares outstanding for the calculation of diluted net loss per common share does not include the following adjustments for potential common shares below because their effects were determined to be antidilutive for the periods presented.

			Three Months Ended March 31,
			2026						2025
Restricted stock unit awards			1,079,041						—
Outstanding stock options			281,118						—
Performance stock unit awards			350,833						—
Potential common shares			1,710,992						—

10. Income Taxes

The effective tax rates for the Company were 29.2% and 18.5% for the three months ended March 31, 2026 and March 31, 2025, respectively.

The increase in the effective tax rate for the three months ended March 31, 2026 was primarily due to the timing of stock-based compensation adjustments, partially offset by limits on the deductibility of executive compensation.

13

11.    Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities

Selected cash payments, receipts, and non-cash activities are as follows (in thousands):

			Three Months Ended March 31,
			2026						2025
Cash paid for interest			$	318					$	343
Cash paid for income taxes			15						23
Non-cash activities:
Issuance of shares pursuant to employee stock purchase plan			835						848

        

12. Commitments and Contingencies

Profit Share Payments

On March 15, 2024, the Company entered into an Asset Purchase Agreement (the “TELA APA”) with TELA Bio, Inc. (“TELA”) to obtain exclusive rights to sell and market a 510(k)-cleared collagen particulate xenograft product in the United States. Pursuant to the TELA APA, the Company is required to make payments (the “Profit Share Payments”) of between a minimum of $3.0 million and a maximum of $7.0 million based on MIMEDX’s net sales of the product over the two years following its commercialization of the product, which occurred during the second quarter of 2024. The company’s remaining obligation of Profit Share Payments to TELA as of March 31, 2026 was $1.3 million.

As of March 31, 2026, the fair value for the minimum amount of Profit Share Payments was $1.3 million. This amount reflects the anticipated timing of such Profit Share Payments, discounted to present value at a discount rate approximating the Company’s borrowing rate plus a risk premium, all of which reflect Level 3 inputs. This amount is reflected as part of other current liabilities in the unaudited condensed consolidated balance sheet.

Litigation and Regulatory Matters

In the ordinary course of business, the Company and its subsidiaries may be a party to pending and threatened legal, regulatory, and governmental actions and proceedings (including those described below). In view of the inherent difficulty of predicting the outcome of such matters, particularly where the plaintiffs or claimants seek very large or indeterminate damages or where the matters present novel legal theories or involve a large number of parties, the Company generally cannot predict what the eventual outcome of the pending matters will be, what the timing of the ultimate resolution of these matters will be, or what the eventual recovery, loss, fines or penalties related to each pending matter may be. The Company's unaudited condensed consolidated balance sheet as of March 31, 2026 reflects the Company's current best estimate of probable losses associated with these matters, including costs to comply with various settlement agreements, where applicable. For more information regarding the Company’s legal proceedings, refer to Note 18, “Commitments and Contingencies” in the 2025 Form 10-K.

In accordance with applicable accounting guidance, the Company accrues a liability when those matters present loss contingencies that are both probable and estimable.

The following is a description of certain litigation and regulatory matters to which the Company is a party:

AXIOFILL

The Company received a Warning Letter from the FDA on December 21, 2023, relating to the inspections and classification of AXIOFILL. The Company received a determination letter in March 2024 reaffirming the FDA’s position that AXIOFILL does not meet the regulatory classification requirements of a Human Cell, Tissue or Cellular or Tissue-based Product under Section 361 of the Public Health Service Act. The Company strongly disagrees with this determination. On March 25, 2024, MIMEDX filed suit in the U.S. District Court for the Northern District of Georgia alleging violations of the Administrative Procedure Act and asking the Court to vacate FDA’s designation, declare FDA’s designation as arbitrary, capricious, an abuse of discretion, and contrary to law, and declare that AXIOFILL meets the criteria to be regulated under Section 361 of the Public Health Services Act. The parties each filed motions for summary judgment in the case. On September 25, 2025, the court denied both summary judgment motions without prejudice and requested additional briefing, which occurred on January 30, 2026

13.     Revenue

MIMEDX has two product categories: (1) Surgical, which reflects products principally used in surgical settings, including the closure of acute wounds or to protect and reinforce tissues and/or regions of interest, and (2) Wound, which reflects products

14

typically used in Advanced Wound Care settings, including the treatment of chronic, non-healing wounds. The Company manages its product portfolio and pipeline based upon opportunities in each of these settings.

Below is a summary of net sales by product line (in thousands):

			Three Months Ended March 31,
			2026						2025
Surgical			$	36,374					32,132
Wound			22,617						56,073
Net sales			$	58,991					$	88,205

The Company did not have significant foreign operations or a single external customer from which 10% or more of net sales were derived during the three months ended March 31, 2026 or 2025.

14.     Segment Information

The Company determines its operating segments based on how the Chief Operating Decision Maker (“CODM”) reviews the business and makes resource allocation decisions. The Company concluded that Joseph Capper, the Company’s Chief Executive Officer, is the CODM.

The Company has a single operating segment, which has not been aggregated with other operating segments.

The CODM uses several measures of profit or loss to assess Company performance and allocate resources. Of these measures, net income is the measure that most aligns to GAAP. Other measures used by the CODM include adjusted earnings before interest, taxes, depreciation and amortization. The CODM assesses actual results against budgets and forecasts, and uses this information to inform various strategic investments into the Company’s operations, including headcount and compensation.

Each financial statement caption included on the condensed consolidated statements of operations reflects a significant segment expense evaluated by the CODM. In addition to this, the CODM also evaluates selling and marketing expense and general and administrative expense, both of which are components of selling, general, and administrative expense on the condensed consolidated statements of operations.

The below table presents selling and marketing and general administrative expense (amounts in thousands):

						Three Months Ended March 31,
						2026						2025
Selling and marketing						$	43,912					$	46,861
General and administrative						9,319						13,108
Selling, general and administrative						$	53,231					$	59,969

Below is a breakout of interest expense and interest income (amounts in thousands):

						Three Months Ended March 31,
						2026						2025
Interest income						$	1,288					$	984
Interest expense						(402)						(478)
Interest expense, net						$	886					$	506

To see depreciation expense, amortization expense, income tax expense, and significant noncash items for this segment please refer to Note 5, Property and Equipment, Net, Note 6, Intangible Assets, Net, Note 10, Income Taxes, Note 11, Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities, respectively.

The CODM is not provided and does not review segment assets at a different asset level or category than the presentation on the consolidated balance sheet.

15. Investments

Vaporox Agreement

15

Late in the second quarter of 2025, the Company entered into a Convertible Note Purchase Agreement (the “Vaporox Note”) with Vaporox, Inc.(“Vaporox”) for $2.0 million. The note matures in the second quarter of 2028, and contains certain contingent conversion features upon the occurrence of specified events. The Vaporox Note was funded early in the third quarter of 2025.

The Company elected to account for the Vaporox Note pursuant to the Fair Value Option guidance prescribed by Accounting Standards Codification (“ASC”) Topic 825. Management chose this optional guidance for ease of calculation. This requires the Company to measure the Fair Value of the Vaporox Note, in its entirety, at each reporting date. As a result of electing the fair value option, direct costs and fees related to the Vaporox Note are expensed as incurred.

As of March 31, 2026, the fair value of the note was $2.1 million, and was estimated using relevant valuation techniques and a series of Level 3 inputs.

Regen Lab

In December 2025, MiMedx entered into a Distributorship Agreement (the “Regen Agreement”) with Regen Lab USA LLC (“Regen Lab”), which provides the Company with the exclusive right to distribute their RegenKit®-Wound Gel in the United States.

The Regen Agreement was accounted for as an acquisition of assets. All costs of acquisition were allocated to the distributorship agreement and is reflected as a component of intangible assets, net, in the unaudited condensed consolidated balance sheet as of March 31, 2026.

In satisfaction of the obligation created by the Regen Agreement, the Company paid Regen Lab an up-front payment of $5.0 million during January 2026. In addition, the Company may be required to pay up to an additional $5.0 million in contingent consideration upon achievement of cumulative revenue milestones specified in the Regen Agreement.

16. Subsequent Events

Cost Reduction Initiative

In April 2026, the Company announced a cost reduction initiative intended to streamline operations and reduce operating expenses in response to a slower‑than‑expected recovery in the Wound Care market following the implementation of the January 1, 2026 Medicare reimbursement changes. These actions included a reduction in force affecting approximately 15% of the Company’s workforce. The Company expects to incur one-time expenses of approximately $4 million during the second quarter of 2026 related to these actions.

Town Park Lease Amendment

In April 2026, the Company amended its lease agreement related to one of its manufacturing facilities in Kennesaw, Georgia. The amendment provides for additional space and extends the existing lease term by 11 years through January 2038. Over the extended term of the lease, the Company will pay $9.8 million in rent payments.

16

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Executive Summary

During the first quarter of 2026, the Company delivered the following financial results:

•Net sales of $59 million, reflecting a 33% decrease over the prior year period. which was comprised of:

◦Surgical net sales of $36 million, reflecting an increase of 13% compared to the prior year period; and

◦Wound net sales of $23 million, reflecting a decrease of 60% compared to the prior year period

•GAAP net loss and net loss margin for the first quarter of 2026 of $11 million and 18%, respectively.

•GAAP fully diluted earnings per share for the first quarter of 2026 of $(0.07) compared to $0.05 in the prior year period.

•Cash balance of $160 million, representing a $6 million decrease sequentially and a $53 million increase compared to March 31, 2025.

Additionally during the quarter, the Company launched two new organically developed products, AMNIOFIX® Thyroid Shields and CHORIOFIX™ and entered into an exclusive distribution agreement with Summit Products Group for multiple additional Surgical products, namely G4Derm® Plus, Hydrelix Collagen Matrix and Novaform®.

Overview

MIMEDX is a pioneer and leader focused on helping humans heal. The Company has more than a decade and a half of experience developing and commercializing products used in the treatment of a wide range of Surgical and Wound management applications. All of our products sold in the United States are regulated by the U.S. Food & Drug Administration (“FDA”). We apply Current Good Tissue Practices (“CGTP”) and other applicable quality standards in addition to terminal sterilization to produce our allografts.

This discussion, which presents our results for the three months ended March 31, 2026 and 2025, should be read in conjunction with the unaudited condensed consolidated financial statements and accompanying notes included in this Form 10-Q and the financial statements and accompanying notes and Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed with the SEC on February 25, 2026 (the “2025 Form 10-K”).

Results of Operations

Three Months Ended March 31, 2026 Compared to the Three Months Ended March 31, 2025

			Three Months Ended March 31,
			(in thousands)
			2026						2025						$ Change						% Change
Net sales			$	58,991					$	88,205					$	(29,214)					(33.1)		%
Cost of sales			17,368						16,558						810						4.9		%
Gross profit			41,623						71,647						(30,024)						(41.9)		%
Selling, general and administrative			53,231						59,969						(6,738)						(11.2)		%
Research and development			4,140						3,328						812						24.4		%
Amortization of intangible assets			301						99						202						nm
Interest income, net			886						506						380						75.1		%
Other expense, net			(168)						(145)						(23)						15.9		%
Income tax provision benefit (expense)			4,471						(1,589)						6,060						nm
Net (loss) income from continuing operations			(10,860)						7,023						(17,883)						(254.6)		%

Changes noted as “nm” in the table above indicate that the percentage change is not meaningful.

17

Net Sales

Net sales were $59.0 million for the three months ended March 31, 2026, representing a decrease of $29.2 million, or 33.1%, compared to $88.2 million for the three months ended March 31, 2025.

Sales by product category were as follows (amounts in thousands):

			Three Months Ended March 31,												Change
			2026						2025						$						%
Surgical			$	36,374					$	32,132					$	4,242					13.2		%
Wound			22,617						56,073						(33,456)						(59.7)		%
Total			$	58,991					$	88,205					$	(29,214)					(33.1)		%

Surgical net sales were $36.4 million for the three months ended March 31, 2026, representing an increase of $4.2 million, or 13.2%, compared to $32.1 million for the three months ended March 31, 2025. This increase was driven by continued growth across the AMNIOFIX®, AMNIOEFFECT®, AXIOFILL®, and HELIOGEN™ product lines as adoption expanded across multiple surgical procedures.

Wound net sales were $22.6 million for the three months ended March 31, 2026, representing a decrease of $33.5 million or 59.7%, compared to $56.1 million for the three months ended March 31, 2025. This decline was primarily driven by the Medicare reimbursement changes that went into effect on January 1, 2026, which resulted in reduced reimbursement rates for skin substitute products, created administrative barriers for patients to receive these products and led to lower realized pricing and volumes within the Wound Care business. During the quarter, the Company also saw initial contributions from sales of its RegenKit PRP offering.

Cost of Sales and Gross Profit Margin

Cost of sales were $17.4 million for the three months ended March 31, 2026, representing an increase of $0.8 million, or 4.9%. compared to $16.6 million for the three months ended March 31, 2025. This increase was driven by higher production cost and increased volume in the Surgical business, largely offset by lower volume in the Wound Care business and reduced amortization of acquired intangible assets.

Gross profit margin was 70.6% for the three months ended March 31, 2026, compared to 81.2% for the three months ended March 31, 2025. This decline was primarily driven by lower Wound Care pricing following the Medicare reimbursement changes, as well as unfavorable product mix and higher costs.

Selling, General and Administrative Expense

Selling, general and administrative (“SG&A”) expense was $53.2 million for the three months ended March 31, 2026, compared to $60.0 million for the three months ended March 31, 2025. The following table shows the composition of this expense between selling and marketing (“S&M”) and general and administrative (“G&A”) components (amounts in thousands):

						Three Months Ended March 31,												Change
						2026						2025						$						%
Selling and marketing						$	43,912					$	46,861					$	(2,949)					(6.3)		%
General and administrative						9,319						13,108						(3,789)						(28.9)		%
Selling, general and administrative						$	53,231					$	59,969					$	(6,738)					(11.2)		%

Sales and marketing expenses decreased $2.9 million or 6.3%, year over year, primarily driven by lower commission expense resulting from reduced sales and lower travel and meeting expenses. This decrease was partially offset by higher bad debt expense.

18

General and administrative expenses decreased $3.8 million or 28.9% year over year, due to the reduction of compensation-related costs, primarily related to the reversal of stock-based compensation expense associated with outstanding performance stock unit awards. These savings were largely offset by increased legal and regulatory expenses, including cost associated with the ongoing litigation with certain competitors and certain former employees.

Research and Development Expense

Research and development (“R&D”) expense was $4.1 million for the three months ended March 31, 2026, representing an increase of $0.8 million, or 24.4%, compared to $3.3 million for the three months ended March 31, 2025. This increase was driven by higher costs associated with the ongoing EPIEFFECT randomized clinical trial, as well as continued investment in the development of future products within the Company’s pipeline.

Interest Income, Net

Interest income, net was $0.9 million for the three months ended March 31, 2026, representing an increase of $0.4 million or 75.1% compared to $0.5 million for the three months ended March 31, 2025. This increase was primarily driven by higher average cash balances maintained in the Company’s interest-bearing accounts and a reduction in outstanding debt.

Income Tax Provision

The effective tax rates for the Company were 29.2% and 18.5% for the three months ended March 31, 2026 and March 31, 2025, respectively.

The increase in the effective tax rate for the three months ended March 31, 2026 was primarily due to the timing of stock-based compensation adjustments, partially offset by limits on the deductibility of executive compensation.

Discussion of Cash Flows

Operating Activities

Cash generated by operating activities was $1.9 million during the three months ended March 31, 2026, representing a decrease of $3.4 million, compared to $5.3 million for the three months ended March 31, 2025. This decrease was primarily driven by lower net income, partially offset by significant accounts receivable collections.

Investing Activities

Cash used for investing activities was $5.6 million during the three months ended March 31, 2026, compared to $0.4 million for the three months ended March 31, 2025. This increase reflects a $5.0 million payment to acquire exclusive distribution rights for RegenKit®‑Wound Gel.

Financing Activities

Cash used for financing activities was $2.6 million during the three months ended March 31, 2026, compared to $2.9 million for the three months ended March 31, 2025. Cash used during both periods was primarily driven by stock repurchases to satisfy tax withholding obligations upon vesting of employee equity awards, a principal payment under the Citizens Credit Agreement, and a profit-share payment to TELA Bio, Inc. related to HELIOGEN® sales performance.

Liquidity and Capital Resources

We require capital for our operating activities, including costs associated with the sale of product through direct and indirect sales channels, research and development activities, compliance costs, costs to sell and market our products, regulatory fees, and legal and consulting fees in connection with ongoing litigation and other matters. We generally fund our operating capital requirements through our operating activities and cash reserves. We expect to use capital to invest in the broadening of our product portfolio, including through potential acquisitions, licensing agreements or other arrangements, the international expansion of our business and certain capital projects.

As of March 31, 2026, we had $159.8 million of cash and cash equivalents, total current assets of $240.3 million and total current liabilities of $44.6 million. We had $17.6 million of long term debt outstanding and $75.0 million of availability under our Revolving Credit Facility (as discussed below).

19

The Company is currently paying its obligations in the ordinary course of business. We believe that our cash from operating activities, existing cash and cash equivalents, and available credit under the Citizens Credit Agreement, as defined below, will enable us to meet our operational liquidity needs for the twelve months following the filing date of this Quarterly Report.

Citizens Credit Agreement

On January 19, 2024, the Company entered into the Citizens Credit Agreement, which provided the Company with a $75.0 million Revolving Credit Facility and $20.0 million Term Loan Facility. We had no outstanding borrowings under the Revolving Credit Facility facility as of March 31, 2026. The Term Loan Facility matures on January 19, 2029.

The Citizens Credit Agreement requires that we comply with certain financial covenants, including a maximum total net leverage ratio and a minimum consolidated fixed charge coverage ratio, as well as other customary restrictive covenants.

As of March 31, 2026, the Company has $17.6 million of principal outstanding on the Term Loan Facility that bears interest at 6.0% and no borrowings outstanding under the Revolving Credit Facility.

Contractual Obligations

There were no significant changes to our contractual obligations during the three months ended March 31, 2026 from those disclosed in the section Item 7, “Management’s Discussion and Analysis of Financial Condition and Results from Operations”, in the 2025 Form 10-K.

Critical Accounting Estimates

In preparing financial statements, we follow accounting principles generally accepted in the United States, which require us to make certain estimates and apply judgments that affect our financial position and results of operations. We regularly review our accounting policies and financial information disclosures. A summary of critical accounting estimates in preparing the financial statements was provided in our Annual Report in the 2025 Form 10-K. There were no new critical accounting estimates applied in the preparation of this Form 10-Q.

Recent Accounting Pronouncements

For the effect of recent accounting pronouncements, see Note 2, Significant Accounting Policies, to the unaudited condensed consolidated financial statements contained herein.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

We are exposed to risks associated with changes in interest rates that could adversely affect our results of operations and financial condition. We do not hedge against interest rate risk.

There have been no material changes in market risk from the information provided in “Item 7A. Quantitative and Qualitative Disclosures about Market Risk” in the 2025 Form 10-K.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended, or the Exchange Act) as of the end of the period covered by this report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this report were effective at a reasonable assurance level in ensuring that information required to be disclosed by us in reports that we file or submit under the Exchange Act (i) is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (ii) accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely discussions regarding required disclosure. We believe that a control system, no matter how well designed and operated, cannot provide absolute assurance that the objectives of the control system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected.

20

Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) of the Exchange Act) that occurred during the fiscal quarter ended March 31, 2026 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

21

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

The Company and its subsidiaries are parties to numerous claims and lawsuits arising in the ordinary course of its business activities, some of which involve claims for substantial amounts. The ultimate outcome of these suits cannot be ascertained at this time.

Item 1A. Risk Factors

There have been no material changes to the Company’s risk factors included in the 2025 Form 10-K.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities

Not applicable.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

Insider Trading Arrangements and Policies

During the three months ended March 31, 2026, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.

Item 6. Exhibits

Exhibit Number						Description
31.1 #						Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2 #						Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1 #						Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2 #						Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS #						XBRL Instance Document
101.SCH #						XBRL Taxonomy Extension Schema Document
101.CAL #						XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF #						XBRL Taxonomy Extension Definition Linkbase Document
101.LAB #						XBRL Taxonomy Extension Label Linkbase Document
101.PRE #						XBRL Taxonomy Extension Presentation Linkbase Document

# Filed or furnished herewith

SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

22

April 29, 2026			MIMEDX GROUP, INC.
			By:			/s/ Doug Rice
						Doug Rice
						Chief Financial Officer
						(duly authorized officer)

23

FAQ

How did MiMedx (MDXG) perform financially in Q1 2026?

MiMedx reported Q1 2026 net sales of about $59.0 million, down 33.1% from a year earlier, and a $10.9 million net loss versus prior net income of $7.0 million. The decline was mainly due to weaker Wound segment sales and lower gross margins.

What happened to MiMedx’s Wound and Surgical segment sales in Q1 2026?

In Q1 2026, MiMedx’s Surgical sales rose to $36.4 million, up 13.2% year over year, while Wound sales dropped to $22.6 million, down 59.7%. The Wound decline was primarily linked to new Medicare reimbursement rules for skin substitutes that reduced pricing and volumes.

What is MiMedx’s cash and debt position as of March 31, 2026?

As of March 31, 2026, MiMedx held $159.8 million in cash and cash equivalents and had $44.6 million in current liabilities. Long‑term debt outstanding totaled $17.6 million on its term loan, with an additional $75.0 million revolving credit facility fully available.

How did Medicare reimbursement changes impact MiMedx (MDXG) in Q1 2026?

Medicare reimbursement changes effective January 1, 2026 reduced MiMedx’s skin substitute reimbursement, contributing to a 59.7% decline in Wound segment revenue to $22.6 million. The changes also pressured pricing and volumes, helping drive overall net sales down 33.1% and compressing margins.

What cost reduction actions is MiMedx implementing in 2026?

In April 2026, MiMedx began a cost reduction initiative to address weaker Wound demand, including a workforce reduction of about 15%. The company expects roughly $4 million of one‑time expenses in Q2 2026 related to these actions aimed at lowering ongoing operating costs.

What strategic investments did MiMedx make in Q1 2026?

During Q1 2026, MiMedx paid $5.0 million upfront for exclusive U.S. distribution rights to RegenKit Wound Gel, recorded in intangible assets. It also continued funding R&D, which increased to $4.1 million, partly for the ongoing EPIEFFECT randomized clinical trial and pipeline development.

Filing Exhibits & Attachments

9 documents

Financial & Certifications

• EX-31.1 EX-31.1 9.5 KB
• EX-31.2 EX-31.2 9.6 KB
• EX-32.1 EX-32.1 5.2 KB
• EX-32.2 EX-32.2 5.4 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 31.2 KB
• EX-101 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT 62.3 KB
• EX-101 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT 103.6 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT 429.1 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT 289.2 KB